ENGOT Rare Tumour Group

Mission Statement

• We aim to accelerate the development of new therapies derived from a solid scientific rational for women with rare gynaecological cancer through European collaboration.

• We aim at using the multidisciplinary expertise available within ENGOT to develop trials covering an area of clear unmet need.

• We aim at strengthening the scientific basis including in these initiative, a strong collaboration with the translational group, and biobanking activities.

Objectives

• To develop a network of collaborations among centers and investigators within ENGOT to design clinical trials with strong scientific rational in rare gynaecological cancer.

• To develop novel trial designs that allow efficient assessment of new compounds and make it feasible to also investigate rare histological and molecular subtypes.

• To offer pharmaceutical companies a read-to-go, efficient structure and academic expertise for accelerated clinical development of their compounds in their pipeline.

• To involve all the groups in this strategic plan that will allow ENGOT to promote a significant gain in the clinical outcomes of many rare tumours.

Working Group Chairs

For contact details of the Chairs, please reach out to ENGOT Office at engot@esgo.org. Elections for the next Chair-Elects will take place in 2027.